Effective Care Coordination Practices Across the CAR T-Cell Therapy Care Continuum

Availability

On-Demand

Cost

$0.00

ACCC's Effective Care Coordination Practices Across the CAR T-Cell Therapy Care Continuum e-course equips the multidisciplinary cancer care team with actionable strategies to improve patient access to CAR T-cell therapy and strengthen care continuity between referring programs and CAR T-cell therapy centers.

Through this brief online course, oncology professionals will be able to:

Identify key components of care continuity across the CAR T-cell therapy continuum
Describe the importance of early referral for patients with hematologic malignancies undergoing CAR T-cell therapy evaluation
Locate practical resources to support patients and caregivers throughout the care continuum

Laurie Adami
Patient Advocate and Volunteer
Blood Cancer United

Laurie Adami is a patient advocate and volunteer with Blood Cancer United (formerly the Leukemia & Lymphoma Society), where she serves as a First Connection volunteer supporting newly diagnosed and relapsed blood cancer patients, a Public Policy Volunteer Advocate, and a member of the Board of Trustees in Los Angeles. She also volunteers with the Lymphoma Research Foundation as a Patient Ambassador and with the Cancer Research Institute as an ImmunoAdvocate.

Diagnosed with stage IV follicular non-Hodgkin lymphoma at age 46 in 2006, Laurie underwent 12 years of continuous treatment across seven lines of therapy, including three clinical trials, before receiving CAR T-cell therapy in 2018 and achieving complete remission. She spent 25 years in financial services, including as president of Los Angeles-based Capital Management Sciences, before retiring to focus on her health. In 2023, she received the Leukemia & Lymphoma Society's National Volunteer De Villiers Family Legacy Award for her volunteer work in patient and legislative advocacy. Laurie majored in Russian language and International Relations at Colgate University and lives in the Hollywood Hills in Los Angeles.

Karen Costello, MSS, LSW, OSW-C
Strategic Director, National Navigation Roundtable
American Cancer Society

Karen Costello, MSS, LSW, OSW-C, is the strategic director of the National Navigation Roundtable (NNRT) at the American Cancer Society. With 30 years of oncology experience as a clinic coordinator, social worker, navigator, and administrator across academic cancer centers, hospitals, and non-profit patient advocacy organizations, she previously served as lead navigator at Cancer Support Community's headquarters, where she built the organization's patient navigation program for patients and caregivers on its Helpline. Earlier in her career, she held roles with the Abramson Cancer Center of the University of Pennsylvania and The Leukemia & Lymphoma Society.

Costello is a licensed social worker in Pennsylvania, holds Oncology Social Work certification from the Board of Oncology Social Work (BOSW), and has been American Cancer Society Leadership in Oncology Navigation (ACS LION) credentialed since 2024. She earned her master's degree in social work and social services from Bryn Mawr Graduate School of Social Work and Social Research.

Caron A. Jacobson, MD, MMSc
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute

Caron A. Jacobson, MD, MMSc is the medical director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute, with oversight of the commercial and research programs for engineered cellular therapies across hematologic malignancies and solid tumors. An associate professor of medicine at Harvard Medical School and a lymphoma clinical investigator, she serves as principal investigator for several CAR T-cell studies and is board certified in hematology, internal medicine, and medical oncology.

Jacobson earned her MD from Columbia University College of Physicians & Surgeons, completed her internal medicine residency at New York-Presbyterian Hospital/Columbia, and completed her hematology/oncology fellowship and MMSc at Dana-Farber/Partners CancerCare.

Mihir Raval, MD, MPH
Hematology Cell Therapy Lead
New York Oncology Hematology (NYOH)

Mihir Raval, MD, MPH, is the hematology cell therapy lead at New York Oncology Hematology, practicing in the Albany, NY area and affiliated with Albany Medical Center. He is board certified in internal medicine, hematology, and medical oncology.

Raval earned his MBBS from Smt. N.H.L. Municipal Medical College in Ahmedabad, India, and his Master of Public Health from West Chester University of Pennsylvania. He completed his internal medicine residency — serving as chief resident — at the University of North Dakota, followed by a hematology/oncology fellowship, where he also served as chief fellow, at the University of Arkansas for Medical Sciences.

Robert Richards, MS, MBA
Corporate Director, Cell Therapy and Transplant
Penn Medicine - University of Pennsylvania Health System

Robb Richards, MS, MBA is the corporate director of the Cell Therapy and Transplant program at Penn Medicine, with oversight of both commercial and research work, as well as a focus on expansion into community hospitals within the Penn system. With over 20 years of experience in oncology (including bone marrow transplant and CAR T-cell therapy), oncology analytics, EMR integration, information technology, business management of oncology practices, he has been the lead in overseeing the implementation and operations of CAR T-cell therapy for commercial use.

Richards earned his MS and MBA from St. Joseph’s University in Pennsylvania, specializing in oncology informatics, and his bachelor’s degree from Drexel University.